Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
Leukoencephalopathy, Progressive Multifocal, HIV Infections
About this trial
This is an interventional treatment trial for Leukoencephalopathy, Progressive Multifocal focused on measuring Leukoencephalopathy, Progressive Multifocal, HIV infections, HIV Fusion Inhibitors
Eligibility Criteria
Inclusion Criteria: 18 years of age and older Have confirmed laboratory diagnosis of HIV infection Presenting with a clinical history of active PML evolving (or continuing to deteriorate) for less than 90 days Diagnosis of PML documented for less than 30 days at the inclusion by cerebral imaging (MRI) AND the absence of another demonstrated etiology AND the detection of JCV DNA in the CSF by qualitative PCR. Signed written inform consent Exclusion Criteria: Concomitant opportunistic infection of the central nervous system Pregnancy, breast-feeding Co-infection by the HIV2 History of immunotherapy including interleukin-2 and alpha-interferon History of treatment by FUZEON® or by cidofovir Contra-indication to receive FUZEON
Sites / Locations
- Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre